Professor Mark Kendall a Biomedical Engineer and innovator with more than 16 years of experience researching the field of needle-free gene and drug delivery to skin (authoring > 300 papers). Mark is an inventor of more than 100 patents – and has worked closely with industrial partners, from concept to commercialisation. First, his Biolistics technology has been successfully commercialised with PowderMed purchased by Pfizer for $400 M in 2006. Mark joined the University of Queensland in 2006 for a Professorial position after 8 years at the University of Oxford, where he was Associate Director of the PowderJect Centre for Gene and Drug Delivery Research, a University Research Lecturer and College Lecturer (Magdalen College). He co-founded Vaxxas, with $15 M of investment to commercialize the Nanopatch. Awards include being a 2012 Rolex Laureate for Enterprise; The Winner of the Australian Innovation Challenge 2011; Australia Museum Eureka Prize 2011; Younger Engineer of Britain 2004.
Vaccines have produced one of the largest increases in the age of life expectancy in human history. However massive challenges remain, with 17 million deaths per year due to infectious disease – mostly in the developing world.
Syringes have been used since 1853, but the needle is holding back the safe and effective syringe administration of vaccines within the developing world. It places vaccine into muscle, arguably missing our immune “sweet spot”; the liquid vaccines used in needles need refrigeration; and there’s a risk of cross-contamination through needle-stick injuries.
Professor Kendall’s solution is the Nanopatch – conceived to tackle all three of these needle-based problems. Professor Kendall will speak about the challenges of vaccine delivery and take the audience on the Nanopatch journey, from idea towards clinical utility as a medical device.
This talk is co-sponsored by:
Event Manager: Mitchell Piercey
Phone: (02) 6201 9462
Professor Mark Kendall a Biomedical Engineer and innovator with more than 16 years of experience researching the field of needle-free gene and drug delivery to skin (authoring > 300 papers). Mark is an inventor of more than 100 patents – and has worked closely with industrial partners, from concept to commercialisation. First, his Biolistics technology has been successfully commercialised with PowderMed purchased by Pfizer for $400 M in 2006. Mark joined the University of Queensland in 2006 for a Professorial position after 8 years at the University of Oxford, where he was Associate Director of the PowderJect Centre for Gene and Drug Delivery Research, a University Research Lecturer and College Lecturer (Magdalen College). He co-founded Vaxxas, with $15 M of investment to commercialize the Nanopatch. Awards include being a 2012 Rolex Laureate for Enterprise; The Winner of the Australian Innovation Challenge 2011; Australia Museum Eureka Prize 2011; Younger Engineer of Britain 2004.
Vaccines have produced one of the largest increases in the age of life expectancy in human history. However massive challenges remain, with 17 million deaths per year due to infectious disease – mostly in the developing world.
Syringes have been used since 1853, but the needle is holding back the safe and effective syringe administration of vaccines within the developing world. It places vaccine into muscle, arguably missing our immune “sweet spot”; the liquid vaccines used in needles need refrigeration; and there’s a risk of cross-contamination through needle-stick injuries.
Professor Kendall’s solution is the Nanopatch – conceived to tackle all three of these needle-based problems. Professor Kendall will speak about the challenges of vaccine delivery and take the audience on the Nanopatch journey, from idea towards clinical utility as a medical device.
This talk is co-sponsored by:
Event Manager: Mitchell Piercey
Phone: (02) 6201 9462
© 2024 Australian Academy of Science
